{"id":"NCT00591773","sponsor":"Takeda","briefTitle":"Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension","officialTitle":"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Chlorthalidone in Subjects With Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2008-01-11","resultsPosted":"2011-04-19","lastUpdate":"2011-04-19"},"enrollment":551,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Azilsartan medoxomil and chlorthalidone","otherNames":["TAK-491","Edarbi"]},{"type":"DRUG","name":"Azilsartan medoxomil and chlorthalidone","otherNames":["TAK-491","Edarbi"]},{"type":"DRUG","name":"Chlorthalidone","otherNames":["Thalitone"]}],"arms":[{"label":"Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD","type":"EXPERIMENTAL"},{"label":"Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD","type":"EXPERIMENTAL"},{"label":"Chlorthalidone 25 mg QD","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with chlorthalidone in treating individuals with essential hypertension, compared to treatment with chlorthalidone alone.","primaryOutcome":{"measure":"Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.","timeFrame":"Baseline and Week 6.","effectByArm":[{"arm":"Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD","deltaMin":-31.72,"sd":0.966},{"arm":"Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD","deltaMin":-31.3,"sd":0.973},{"arm":"Chlorthalidone 25 mg QD","deltaMin":-15.85,"sd":0.957}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":46,"countries":["United States"]},"refs":{"pmids":["30175930"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":184},"commonTop":["Dizziness","Headache","Plasminogen activator inhibitor increased","Hypokalaemia"]}}